Jerry Lee

Chief Science and Innovation Officer

Ellison Institute of Technology

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Jerry Lee serves as the Chief Science and Innovation Officer at the Ellison Institute of Technology in the United States. His research interests encompass a wide range of topics including immune-related adverse events linked to immunotherapy, proteogenomic analyses of tumors, and applications of machine learning in biomedical imaging. Dr. Lee has contributed significantly to understanding cancer biomarkers, epidemiological trends, and treatment outcomes, which are evident in his recent publications.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (4)

Nathanael Fillmore

Assistant Professor of Medicine

Harvard Medical School

UNITED STATES

View details

Mariaelena Pierobon

Associate Professor

George Mason University

UNITED STATES

View details

Tracey Pèrez Koehlmoos

Uniformed Services University of the Health Sciences

UNITED STATES

View details

Robert Grossman

University of Chicago

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jerry Lee

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Phenotyping Hepatic Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy

Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.

Nondestructive, quantitative viability analysis of 3D tissue cultures using machine learning image segmentation

Detecting Disruption of HER2 Membrane Protein Organization in Cell Membranes with Nanoscale Precision

BLOODPAC: Collaborating to chart a path towards blood‐based screening for early cancer detection

Chemotherapy Treatment Costs and Clinical Outcomes of Colon Cancer in the U.S. Military Health System’s Direct and Private Sector Care Settings

KRAS Sequence Variation as Prognostic Marker in Patients With Young- vs Late-Onset Colorectal Cancer.

Trends in Epidemiology of Esophageal Cancer in the US, 1975-2018

An Inflection Point in Cancer Protein Biomarkers: What was and What's Next

Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways.

Collaborators (4)

Nathanael Fillmore

Mariaelena Pierobon

Tracey Pèrez Koehlmoos

Robert Grossman

Make your next move.